|Bid||4.80 x 4000|
|Ask||5.25 x 2200|
|Day's range||4.88 - 5.10|
|52-week range||3.80 - 13.41|
|Beta (3Y monthly)||3.15|
|PE ratio (TTM)||N/A|
|Earnings date||7 Feb 2019 - 11 Feb 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.63|
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla® (ado-trastuzumab emtansine) to OMERS, the defined benefit pension plan for municipal employees in the Province of Ontario, Canada, for $65 million. “ImmunoGen played a key role in the generation and early development of Kadcyla, the first ADC approved for the treatment of HER2-positive breast cancer, and we are pleased to see the continued progress of this important therapy in the market,” said Mark Enyedy, President and Chief Executive Officer. This transaction entails the sale of the residual interest held by ImmunoGen from a prior transaction with Immunity Royalty Holdings, L.P. (IRH).
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 8:30am PT (11:30am ET) on January 9, 2019. Following the presentation, Mr. Enyedy will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 9:00am PT (12:00pm ET).
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Initial Data for CD123-Targeting IMGN632 Demonstrate Encouraging Anti-Leukemia Activity and Tolerable Safety Profile in Both AML and BPDCN; Dose Exploration Continues
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David B. Johnston has stepped down as Chief Financial Officer of the Company, with immediate effect. Mr. Johnston will remain employed with the Company through the end of 2018 and thereafter will serve as a consultant to provide transitional support. David Foster, Vice President of Finance and Chief Accounting Officer, will continue to oversee ImmunoGen’s Finance and Accounting functions.
Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
Investors slowly backed away from the stock in anticipation of a big data release, which ended up landing with a thud later in the month.
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
ImmunoGen (IMGN) delivered earnings and revenue surprises of 8.82% and -8.32%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for restructuring costs, came to 31 cents per share. The results surpassed Wall Street expectations. ...
Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer